ArticleThe EPMA journal2026
Validated semi-supervised early and accurate screening for anterior segment diseases: a 3PM-guided conceptual and technological innovation.
Article in The EPMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aims: Ocular anterior segment diseases are major causes of global visual impairment. Early and accurate detection of anterior segment abnormalities is essential to support predictive diagnostics, targeted prevention, and individualized treatments management. Conventional slit-lamp assessments are often limited by human observation and inter-clinician variability, restricting their ability to achieve rapid and large-scale disease screening. To advance anterior segment care within the predictive, preventive, and personalized medicine (PPPM/3PM) framework, this study aimed to develop a comprehensive and validated semi-supervised object detection (SSOD) system for slit-lamp imaging-based screening of multiple anterior segment diseases. Methods: A total of 7230 slit-lamp images from 3302 patients were retrospectively collected at the Second Affiliated Hospital of Zhejiang University between November 2016 and July 2024. The proposed SSOD integrated a Category Control Embed (CCE) module to mitigate class imbalance and an Out-of-distribution Detection Fusion Classifier (ODDFC) to identify previously unseen lesions. Model performance was quantitatively compared with YOLOv8 and ophthalmologists using quantitative metrics (average precision [AP], recall) and clinical assessments of diagnostic accuracy, lesion comprehensiveness, and localization precision. Results: The SSOD achieved mAP comparable to YOLOv8 (0.729 vs. 0.725 for single-lesion; 0.538 vs. 0.543 for multi-lesion), but demonstrated substantially higher recall (0.893 vs. 0.656 for single-lesion; 0.679 vs. 0.477 for multi-lesion). In clinical evaluations, SSOD scored 2.430/3 for single-lesion and 1.942/3 for multi-lesion detection, outperforming YOLOv8 and approaching the performance of junior ophthalmologists in multi-lesion cases. Conclusion: The SSOD framework offers an efficient and scalable solution for anterior segment disease screening, delivering reliable multi-lesion detection with minimal annotation. It supports early recognition of anterior segment lesions, guides targeted interventions to prevent irreversible vision loss, and facilitates patient-centered, individualized management that advances ophthalmic care from reactive assessment to proactive precision treatment, aligning with the principles of 3PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.